Results 211 to 220 of about 6,173,935 (359)

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Systematic review of prophylactic vs rescue surfactant [PDF]

, 1997
Colin J. Morley
openalex   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Systematic review of near patient test evaluations in primary care [PDF]

, 1999
Brendan Delaney, Christopher Hyde, Richard J. McManus, Shawn Wilson, David Fitzmaurice, Sue Jowett, R S Tobias, G. H. G. Thorpe, Richard Hobbs   +8 more
openalex   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Meta-analysis, collaborative overview, systematic review: what does it all mean?

, 1997
Mike Clarke, Davina Ghersi
openalex   +1 more source

How often does surgery for peptic ulceration eradicate Helicobacter pylori? Systematic review of 36 studies [PDF]

, 1998
John Danesh, P N Appleby, Richárd Pető
openalex   +1 more source

Monkeypox in South Asia: a systematic review. [PDF]

Emerg Microbes Infect
Wangdi K, Adhikary R, Liu Z, Vardoulakis S, McFarlane RA, Kotepui M, Hu W, Suwannatrai AT, Tsheten T.   +8 more
europepmc   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Efficient literature searching in diffuse topics: lessons from a systematic review of research on communicating risk to patients in primary care [PDF]

, 1999
Elaine Matthews, Adrian Edwards, Jackie Barker, Michael Bloor, Judith Covey, Kerenza Hood, Roisin Pill, Ian Russell, Nigel Stott, Clare Wilkinson   +9 more
openalex   +1 more source